Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | EDNRB | P24530 | 1/20 | 0.47 |
| ▸ | EDNRA | P25101 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20831831 | 0.95 | ESR1 (0.58) | ESR1ESR2MAPTMAPK1TDP1 | |
| SCHEMBL15013033 | 0.95 | ESR1 (0.58) | ESR1ESR2MAPTMAPK1TDP1 | |
| SCHEMBL20831829 | 0.95 | ESR1 (0.58) | ESR1ESR2MAPTMAPK1TDP1 | |
| SCHEMBL15312307 | 0.95 | ESR1 (0.58) | ESR1ESR2MAPTMAPK1TDP1 | |
| SCHEMBL239999 | 0.95 | ESR1 (0.58) | ESR1ESR2MAPTMAPK1TDP1 | |
| SCHEMBL2604720 | 0.95 | ESR1 (0.58) | ESR1ESR2MAPTMAPK1TDP1 | |
| SCHEMBL30362855 | 0.95 | ESR1 (0.58) | ESR1ESR2MAPTMAPK1TDP1 | |
| SCHEMBL22536180 | 0.94 | ESR1 (0.60) | ESR1ESR2MAPTMAPK1TDP1 | |
| SCHEMBL7023880 | 0.94 | ESR1 (0.60) | ESR1ESR2MAPTMAPK1TDP1 | |
| SCHEMBL7023886 | 0.94 | ESR1 (0.60) | ESR1ESR2MAPTMAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10980774-B2 | Combination therapies | MEI PHARMA, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20180015067-A1 | COMBINATION THERAPIES | Aardvark Therapeutics, Inc. | 2018-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10980774-B2 | Combination therapies | PCK2, PDK1, PCK1 | ESR1 2467/4885ESR2 1403/4885MAPT 3327/4885 |
| US-20180015067-A1 | COMBINATION THERAPIES | PCK2, PDK1, PCK1 | ESR1 2467/4885ESR2 1403/4885MAPT 3327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.